Trial Profile

A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Troriluzole (Primary)
Indications Obsessive-compulsive disorders
Focus Adverse reactions
Sponsors Biohaven Pharmaceuticals

Most Recent Events

17 Jan 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
17 Jan 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
13 Apr 2024 According to Biohaven Therapeutics media release, data from the study will be presented as both oral and poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com